Josh Levitsky, MD
Gastroenterology · Chicago, ILNPI 1770573305
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 42.0% of the total. Reporting peaked in 2019 at $73,292 and has fallen 99.6% since, to $286 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $1384.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$111K
- Gilead$48K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Novartis$37K
- Mallinckrodt Enterprises LLC$14K
- BD$6K
- plus $11K from 9 others
Across 6 payments — averaging $7050.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$42K
What the payments were for
- Consulting fees$104,69840%
- Speaking & faculty fees$133,89151%
- Travel & lodging$21,9288%
- Food & beverage$4,0062%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 43 | $111,085 |
| Gilead | 58 | $47,633 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $38,292 |
| Novartis | 31 | $36,573 |
| Mallinckrodt Enterprises LLC | 5 | $13,830 |
| BD | 2 | $5,670 |
| Dynavax Technologies Corporation | 1 | $3,750 |
| Novo Nordisk | 3 | $3,165 |
| Saol Therapeutics Inc. | 1 | $3,000 |
| Merck | 1 | $653 |
| Saol International Limited | 1 | $500 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $83 |
| Madrigal Pharmaceuticals | 1 | $43 |
| Travere Therapeutics, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$44,979
- LIVTENCITY$37,873
- Epclusa$22,149
- Livdelzi$18,568
- Vemlidy$4,700
- Heplisav-B$3,750
- Cytogam$3,000
How this compares
$264,525 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 70 | $108,312 |
| XifaxanRifaximin | 27 | $89,759 |
| Everolimus | 57 | $85,042 |
| Tacrolimus | 244 | $34,102 |
| Ursodiol | 82 | $16,639 |
| Entecavir | 58 | $15,425 |
| Cyclosporine ModifiedCyclosporine, Modified | 28 | $5,363 |
| Mycophenolate Mofetil | 66 | $4,561 |
| Azathioprine | 24 | $2,024 |
| Lactulose | 23 | $424 |
| Prednisone | 81 | $414 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 80 | $344 |
| Carvedilol | 30 | $256 |
| Spironolactone | 13 | $241 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 11 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $47,633 | $108,31270 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $83 | $89,75927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Chicago
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
- Saurabh KapurChicago$532K
- Ikuo HiranoChicago$457K
- Adam SteinChicago$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.